Citation Impact
Citing Papers
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
2012 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Strategy for Dual-Analyte Luciferin Imaging: In Vivo Bioluminescence Detection of Hydrogen Peroxide and Caspase Activity in a Murine Model of Acute Inflammation
2013 StandoutNobel
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
2013
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
The Ensembl Variant Effect Predictor
2016 Standout
Target engagement imaging of PARP inhibitors in small-cell lung cancer
2018
A view on drug resistance in cancer
2019 StandoutNature
Constitutive Activity in Melanocortin-4 Receptor
2014
Monitoring the chromosome 2 intraerythrocytic transcriptome of Plasmodium falciparum using oligonucleotide arrays.
2002
BRCAness revisited
2016
MC4R Agonists: Structural Overview on Antiobesity Therapeutics
2018 StandoutNobel
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
2018
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Mechanisms and insights into drug resistance in cancer
2013
The genetics of ageing
2010 StandoutNature
Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses
2010 StandoutNobel
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
Genetic screens in isogenic mammalian cell lines without single cell cloning
2020
Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer
2015
The Transcriptome of the Intraerythrocytic Developmental Cycle of Plasmodium falciparum
2003 Standout
Cancer-associated cachexia
2018 Standout
Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
2011
Synthetic lethality as an engine for cancer drug target discovery
2019
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Delivery of siRNA mediated by histidine-containing reducible polycations
2008
Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors
2020 StandoutNobel
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation
2006
Extracellular Metabolic Energetics Can Promote Cancer Progression
2015
Caspase Substrates and Inhibitors
2013
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
2015 StandoutNature
Emerging Biological Principles of Metastasis
2017 Standout
PARP Inhibitor Treatment in Ovarian and Breast Cancer
2011
PARP-1 enhances the mismatch-dependence of 5′-directed excision in human mismatch repair in vitro
2011 StandoutNobel
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Synthetic lethality and cancer
2017
The Hallmarks of Aging
2013 Standout
The PI3K Pathway in Human Disease
2017 Standout
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
PARP inhibition: PARP1 and beyond
2010
Aurora kinase inhibitors: Progress towards the clinic
2012
Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor
2004
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
2016
Synthesis, antimicrobial and cytotoxic activities of pyrimidinyl benzoxazole, benzothiazole and benzimidazole
2014
Identification of Mutant Firefly Luciferases that Efficiently Utilize Aminoluciferins
2011
A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry
2014 Standout
The Regulation of Feeding and Metabolic Rate and the Prevention of Murine Cancer Cachexia with a Small-Molecule Melanocortin-4 Receptor Antagonist
2005
Structure and Function of the Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets
2016 StandoutNobel
The Posttranslational Processing of Prelamin A and Disease
2009
Fundamentals of cancer metabolism
2016 Standout
Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts
2012
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
2012 Standout
A Computational Model for Overcoming Drug Resistance Using Selective Dual-Inhibitors for Aurora Kinase A and Its T217D Variant
2013 StandoutNobel
Studying Hepatitis C Virus: Making the Best of a Bad Virus
2007 StandoutNobel
Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity
2004
The Melanocortin-4 Receptor: Physiology, Pharmacology, and Pathophysiology
2010
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
Drug Resistance in Cancer: An Overview
2014 Standout
Interaction of Hepatitis C Virus-Like Particles and Cells: a Model System for Studying Viral Binding and Entry
2002
Works of Luis E. Rodrı́guez being referenced
ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
2009
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
2015
Plasmodium falciparum circumsporozoite (CS) protein peptides specifically bind to HepG2 cells
2001
Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin
2010
Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152
2009
Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells
2002
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors
2008
Identification of 2-{2-[2-(5-Bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl}-4,5-dihydro-1H-imidazole (ML00253764), a Small Molecule Melanocortin 4 Receptor Antagonist That Effectively Reduces Tumor-Induced Weight Loss in a Mouse Model
2004
246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism
2014
Two MSA 2 peptides that bind to human red blood cells are relevant to Plasmodium falciparum merozoite invasion
2000
Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models
2005
Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks
2008
Rationale for the combination of veliparib with platinum-based chemotherapy.
2015
Synthesis and Evaluation of a New Generation of Orally Efficacious Benzimidazole-Based Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors as Anticancer Agents
2009